Komori
Share Issuance and Disposal4575CanBas Co.,Ltd.Pharmaceuticals

Notice Regarding the Issuance of New Shares as Restricted Stock Compensation

Resolved to newly issue 57,000 common shares to 6 directors as restricted stock compensation. The shares may not be transferred for 3 years, and the Company will acquire them for no consideration in certain cases, including resignation.

Worth reading
56In focus
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
57000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of new shares as restricted stock compensation

Who receives how much

57,000 common shares (39,000 for directors (excluding directors who are Audit & Supervisory Committee members), and 18,000 for directors who are Audit & Supervisory Committee members)

3 directors of the Company (excluding directors who are Audit and Supervisory Committee members)39,000 shares
3 of the Company's directors who are Audit & Supervisory Committee members18,000 shares

The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.

¥719 per share
Total issue value

¥40,983,000

Amount of funds to be raised
Total amount to be paid in: ¥40,983,000; estimated net proceeds: Not disclosed
Total Stock-Based Compensation
Total monetary compensation claims: ¥40,983,000 (¥28,041,000 for directors (excluding directors who are Audit & Supervisory Committee members), and ¥12,942,000 for directors who are Audit & Supervisory Committee members)
Conditions on transfer restrictions

Restricted stock is stock awarded as compensation that cannot be sold during a specified period, with the restrictions lifted once the applicable conditions are met.

Transfer restriction period
From 23 October 2026 through 22 October 2029 (3 years)
Conditions for lifting transfer restrictions
All restrictions will be released when the period expires, provided that the relevant directors have continuously held office as directors of the Company throughout the restricted period. If a director resigns for a legitimate reason, the number of shares released and the timing of release will be reasonably adjusted.
Reason for acquisition without consideration
If a director resigns before the restricted period expires without a legitimate reason, if the release conditions are not met and the restrictions are not released, or if the restrictions are not released in connection with a corporate reorganisation.
Categories and Number of Persons Covered
Category Directors (excluding directors serving as Audit and Supervisory Committee members) / Number of Employees 3 / Number of allocated shares 39,000 shares, Category Directors serving as Audit and Supervisory Committee members / Number of Employees 3 / Number of allocated shares 18,000 shares
Intended allottee's holding policy
The shares may not be transferred, pledged, used to establish a security interest by way of transfer, gifted inter vivos, bequeathed or otherwise disposed of in any way from 23 October 2026 through 22 October 2029. The Company will acquire for no consideration any shares that do not meet the release conditions when the restricted period expires.
Payment date
23 October 2026
Basis for determining the amount to be paid
The closing price of the Company's common shares on the Tokyo Stock Exchange on 28 September 2026 was ¥719. No discount or premium rate was stated.
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of new shares as restricted stock compensation
Number of shares to be issued or disposed of57,000 common shares (39,000 for directors (excluding directors who are Audit & Supervisory Committee members), and 18,000 for directors who are Audit & Supervisory Committee members)
Issue price and disposal price¥719 per share
Total issue value¥40,983,000
Amount of funds to be raisedTotal amount to be paid in: ¥40,983,000; estimated net proceeds: Not disclosed
Payment date23 October 2026
Intended allotteeCategory 3 directors of the Company (excluding directors who are Audit and Supervisory Committee members) / Number of Shares 39,000 shares, Category 3 of the Company's directors who are Audit & Supervisory Committee members / Number of Shares 18,000 shares
Intended allottee's holding policyThe shares may not be transferred, pledged, used to establish a security interest by way of transfer, gifted inter vivos, bequeathed or otherwise disposed of in any way from 23 October 2026 through 22 October 2029. The Company will acquire for no consideration any shares that do not meet the release conditions when the restricted period expires.
Basis for determining the amount to be paidThe closing price of the Company's common shares on the Tokyo Stock Exchange on 28 September 2026 was ¥719. No discount or premium rate was stated.
Transfer restriction periodFrom 23 October 2026 through 22 October 2029 (3 years)
Conditions for lifting transfer restrictionsAll restrictions will be released when the period expires, provided that the relevant directors have continuously held office as directors of the Company throughout the restricted period. If a director resigns for a legitimate reason, the number of shares released and the timing of release will be reasonably adjusted.
Reason for acquisition without considerationIf a director resigns before the restricted period expires without a legitimate reason, if the release conditions are not met and the restrictions are not released, or if the restrictions are not released in connection with a corporate reorganisation.
Categories and Number of Persons CoveredCategory Directors (excluding directors serving as Audit and Supervisory Committee members) / Number of Employees 3 / Number of allocated shares 39,000 shares, Category Directors serving as Audit and Supervisory Committee members / Number of Employees 3 / Number of allocated shares 18,000 shares
Total Stock-Based CompensationTotal monetary compensation claims: ¥40,983,000 (¥28,041,000 for directors (excluding directors who are Audit & Supervisory Committee members), and ¥12,942,000 for directors who are Audit & Supervisory Committee members)
Items this document does not state (14)
Estimated issuance expensesSpecific use of fundsDilution RateTotal number of issued sharesExercise priceExercise periodNumber of Stock Acquisition RightsUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To provide directors with an incentive to achieve sustained increases in corporate value and to promote the sharing of value between directors and shareholders.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Issuance of New Shares as Restricted Stock Compensation | CanBas Co.,Ltd. (4575) timely disclosure | Komori